Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th

Alumis’ (NASDAQ:ALMS) lock-up period is set to expire on Wednesday, December 25th. Alumis had issued 13,125,000 shares in its public offering on June 28th. The total size of the offering was $210,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Wall Street Analysts Forecast Growth

ALMS has been the topic of a number of analyst reports. HC Wainwright dropped their target price on Alumis from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Robert W. Baird initiated coverage on shares of Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.83.

Alumis Stock Up 2.4 %

NASDAQ ALMS opened at $8.63 on Friday. The company has a 50 day simple moving average of $10.24. Alumis has a one year low of $7.66 and a one year high of $13.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new position in shares of Alumis in the 3rd quarter valued at about $27,000. MetLife Investment Management LLC purchased a new stake in shares of Alumis in the 3rd quarter valued at about $89,000. Barclays PLC acquired a new stake in shares of Alumis in the 3rd quarter valued at about $197,000. Maven Securities LTD purchased a new position in Alumis during the 2nd quarter worth approximately $332,000. Finally, State Street Corp acquired a new position in Alumis during the third quarter worth approximately $866,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.